Tag: GlobeNewswire

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York

Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand

REYKJAVIK, Iceland, and SEOUL, South Korea, Oct. 06, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract development and manufacturing (CDMO) organization, today announced a long-term strategic manufacturing partnership.

Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply, with the potential to further expand the collaboration over time. The Syracuse facility has 40,000 liters of bioreactor capacity for biologics manufacturing, supported by on-site process development and quality control capabilities. The site has an established track record in commercial biologics manufacturing and recently completed an unannounced FDA inspection with zero observations, further demonstrating its strong quality and regulatory capabilities.

The agreement expands Alvotech’s US-based manufacturing footprint while strengthening its global supply network. The additional capacity complements Alvotech’s existing manufacturing partnerships and its in-house development and manufacturing capabilities, supporting its expanding portfolio and providing greater flexibility to meet demand across international markets.

“Alvotech has one of the most comprehensive, internally developed product portfolios in the industry,” said Lisa Graver, CEO of Alvotech. “With the expansion of our global manufacturing network, we will have sufficient capacity to meet demand for our pipeline for the next ten years. Our collaboration with LOTTE Biologics will bring additional manufacturing capacity in New York to support patients worldwide, complementing our existing capabilities as we scale our portfolio and prepare for future launches.”

“Alvotech’s expertise in biosimilar development, combined with LOTTE Biologics’ manufacturing capabilities, creates a strong foundation for this collaboration,” said James Park, CEO of LOTTE Biologics. “We look forward to strategically supporting Alvotech’s growing portfolio and the reliable supply of high-quality, more affordable biologic medicines to patients worldwide. With our Syracuse operations and the completion of our Songdo Bio Campus, we are committed to providing flexible, dual-site manufacturing support as the partnership grows.”

Commercial supply will be subject to successful technology transfer, manufacturing qualification and applicable regulatory approvals.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our  website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

About LOTTE Biologics

LOTTE Biologics is a global contract development and manufacturing organization (CDMO) providing an integrated biologics solutions to pharmaceutical and biotechnology companies worldwide. With its established commercial manufacturing operations in Syracuse, New York, and the newly completed Songdo Bio Campus in South Korea, LOTTE Biologics is building a flexible, dual-site manufacturing network to support customers from development through commercial supply.

For more information, please visit our website or Linkedin.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6c15cf4e-e469-4260-b8ad-52f6cdb6d66a

EFFINGHAM, Ill., Oct. 06, 2026 (GLOBE NEWSWIRE) — Midland States Bancorp, Inc. (Nasdaq: MSBI) announced today that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC). The registration statement, once declared effective by the SEC, is intended to provide the Company with flexibility to access the capital markets in an efficient manner.

Jeffrey G. Ludwig, President and Chief Executive Officer of Midland, commented, “Filing this universal shelf registration statement is a prudent step in our long-term capital planning. It provides Midland with additional flexibility to support our strategic priorities over time, while maintaining our disciplined approach to capital allocation.”

Under the shelf registration statement, once declared effective by the SEC, Midland may from time to time issue up to $250 million of its securities covered by the registration statement. Currently, the Company has no specific plans to issue any securities under the registration statement. The specifics of any future offering, along with the prices and terms of any such securities offered by Midland, will be determined at the time of any such offering and will be described in detail in a prospectus supplement filed in connection with such offering.

The shelf registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration and qualification under the securities law of such jurisdiction. Any offering of the securities covered by the shelf registration statement will be made solely by means of a prospectus and, if required, an accompanying prospectus supplement relating to that offering. A copy of the prospectus included in the registration statement may be obtained on the SEC’s website at www.sec.gov or the Company’s investor relations website.

About Midland States Bancorp, Inc.

Midland States Bancorp, Inc. is a community-based financial holding company headquartered in Effingham, Illinois, and is the sole shareholder of Midland States Bank. As of June 30, 2026, the Company had total assets of approximately $6.70 billion, and its Wealth Management Group had assets under administration of approximately $4.78 billion. The Company provides a full range of commercial and consumer banking products and services, merchant credit card services, trust and investment management, insurance and financial planning services. For additional information, visit midlandsb.com or follow Midland States Bank on LinkedIn.

CONTACTS:
Claire A. Stack, Chief Financial Officer, at cstack@midlandsb.com or (217) 342-7321

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York

Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand

REYKJAVIK, Iceland, and SEOUL, South Korea (October 6, 2026) – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract development and manufacturing (CDMO) organization, today announced a long-term strategic manufacturing partnership.

Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse facility in New York for global supply, with the potential to further expand the collaboration over time. The Syracuse facility has 40,000 liters of bioreactor capacity for biologics manufacturing, supported by on-site process development and quality control capabilities. The site has an established track record in commercial biologics manufacturing and recently completed an unannounced FDA inspection with zero observations, further demonstrating its strong quality and regulatory capabilities.

The agreement expands Alvotech’s US-based manufacturing footprint while strengthening its global supply network. The additional capacity complements Alvotech’s existing manufacturing partnerships and its in-house development and manufacturing capabilities, supporting its expanding portfolio and providing greater flexibility to meet demand across international markets.

“Alvotech has one of the most comprehensive, internally developed product portfolios in the industry,” said Lisa Graver, CEO of Alvotech. “With the expansion of our global manufacturing network, we will have sufficient capacity to meet demand for our pipeline for the next ten years. Our collaboration with LOTTE Biologics will bring additional manufacturing capacity in New York to support patients worldwide, complementing our existing capabilities as we scale our portfolio and prepare for future launches.”

“Alvotech’s expertise in biosimilar development, combined with LOTTE Biologics’ manufacturing capabilities, creates a strong foundation for this collaboration,” said James Park, CEO of LOTTE Biologics. “We look forward to strategically supporting Alvotech’s growing portfolio and the reliable supply of high-quality, more affordable biologic medicines to patients worldwide. With our Syracuse operations and the completion of our Songdo Bio Campus, we are committed to providing flexible, dual-site manufacturing support as the partnership grows.”

Commercial supply will be subject to successful technology transfer, manufacturing qualification and applicable regulatory approvals.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com

About Alvotech

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our  website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

About LOTTE Biologics

LOTTE Biologics is a global contract development and manufacturing organization (CDMO) providing an integrated biologics solutions to pharmaceutical and biotechnology companies worldwide. With its established commercial manufacturing operations in Syracuse, New York, and the newly completed Songdo Bio Campus in South Korea, LOTTE Biologics is building a flexible, dual-site manufacturing network to support customers from development through commercial supply.

For more information, please visit our website or Linkedin.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

WINTER PARK, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the future of the commodity markets through tokenization, today announced that Christine Plummer, Chief Financial Officer, will present and host in-person one-on-one meetings with investors at the ThinkEquity Conference, taking place on October 15, 2026 at the Mandarin Oriental Hotel in New York City.

Presentation Details

The live presentation will begin at 4:00 p.m. ET on Thursday, October 15, 2026 at the Mandarin Oriental Hotel, 80 Columbus Circle, New York, NY. A live webcast of the presentation will be available on the Events page of the Streamex investor relations website at https://ir.streamex.com/news-events/events. A replay of the webcast will be available for 90 days following the presentation. Streamex will also host in-person one-on-one meetings with investors on Thursday, October 15, 2026. To register for the presentation or to request a one-on-one meeting, please contact ThinkEquity at conference@think-equity.com.

About ThinkEquity

ThinkEquity is a boutique investment bank that provides a suite of capital markets and advisory services to growth companies, including initial public offerings (IPOs), secondary offerings, confidentially marketed public offerings (CMPOs), registered direct offerings, at-the-market offerings (ATMs), debt placement and acquisition financing. The ThinkEquity Conference brings together U.S. and international public and private companies, industry executives, and institutional and accredited investors for company presentations and one-on-one meetings. For more information, visit www.think-equity.com.

About Streamex Corp.

Streamex Corp. (NASDAQ: STEX) is a technology and infrastructure company focused on the tokenization and digitalization of commodity real-world assets. Streamex delivers institutional-grade solutions that bridge traditional finance and blockchain-enabled markets through secure, regulated, and yield-bearing financial instruments.

For more information, visit www.streamex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Streamex’s business strategy, product development, and participation in the ThinkEquity Conference. These statements are based on current expectations and assumptions subject to risks and uncertainties beyond Streamex’s control, and actual results may differ materially, including as a result of market conditions, regulatory developments, and macroeconomic factors affecting digital asset markets. A discussion of these and other factors is set forth in Streamex’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Streamex undertakes no obligation to update any forward-looking statements except as required by law.

Contacts

Laura Kiernan	Christine Plummer
Head of Investor Relations, Streamex Corp.	Chief Financial Officer, Streamex Corp.
IR@streamex.com | 1-914-598-7733	www.streamex.com | X.com/streamex

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE) —

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
09/30/2026	100,732,781	105,563,044

For further information on Cellectis, please contact:         

Media contacts:              
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com  
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93      
    
Investor Relations contact:           
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com   

Attachment

• Voting_Rights_PR_Sept_2026_EN

MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) — USCB FINANCIAL HOLDINGS, INC. (the “Company”) (NASDAQ: USCB) will report financial results for the quarter ended September 30, 2026, after the market closes on Thursday, October 22, 2026.

A conference call to discuss quarterly results will also be held with Chairman, President, and CEO, Luis de la Aguilera, Chief Financial Officer, Robert Anderson, and Chief Credit Officer, Sergio Garrido, details which are provided below.

Live Conference Call and Audio Webcast

Date: Friday, October 23, 2026
Time: 11:00am Eastern Time
Dial-in: (833) 816-1416 (toll free in the U.S.)
Passcode: USCB Financial Holdings Call

A live audio webcast of the call will be available with the press release and slides on the investor relations page of the Company’s website at https://investors.uscenturybank.com/. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the internet broadcast.

A replay of the webcast will be archived on the investor relations page shortly after the conference call has ended.

About USCB Financial Holdings, Inc.

USCB Financial Holdings, Inc. is the bank holding company for U.S. Century Bank. Established in 2002, U.S. Century Bank is one of the largest community banks headquartered in Miami, and one of the largest community banks in the state of Florida. U.S. Century Bank is rated 5-Stars by BauerFinancial, the nation’s leading independent bank rating firm. U.S. Century Bank offers customers a wide range of financial products and services and supports numerous community organizations, including the Greater Miami Chamber of Commerce, the South Florida Hispanic Chamber of Commerce, and ChamberSouth. For more information or to find a U.S. Century Bank banking center near you, please call (305) 715-5200 or visit www.uscentury.com.

Contacts:

Investor Relations
InvestorRelations@uscentury.com 

Media Relations
Martha Guerra-Kattou
MGuerra@uscentury.com

MINEOLA, N.Y., Oct. 06, 2026 (GLOBE NEWSWIRE) — Hanover Bancorp, Inc. (Nasdaq: HNVR) (the “Company”), parent company of Hanover Community Bank (the “Bank”), today announced the opening of its newest full-service branch at 205 Osborn Avenue, Riverhead, New York. This location is Hanover Bank’s eleventh branch. It reflects Hanover’s disciplined growth strategy of expanding into communities with strong economic momentum and further expands its presence on Long Island, particularly in Suffolk County. Together with its Hauppauge Business Center and Port Jefferson branch, the Riverhead branch strengthens the Bank’s ability to serve this region with local decision-making, personalized service, and comprehensive financial solutions.

“Riverhead is a natural fit for Hanover’s continued growth across Long Island,” said Michael P. Puorro, Chairman and Chief Executive Officer of Hanover Community Bank. “The community is experiencing a remarkable transformation, and we see tremendous opportunity to partner with local businesses, families, community organizations, and public-sector leaders. As we evaluated where to grow next, Riverhead stood out as a market where our relationship-focused approach and professional expertise can make a meaningful difference. We look forward to building lasting relationships and supporting the community’s continued success.”

The Riverhead branch also serves as a business banking center offering a full range of personal, business, and municipal banking services. This location is staffed with dedicated business bankers who can provide local businesses with direct access to their years of banking expertise and support their growth.

“Our strategy has never been simply to open branches; it is to become part of the communities we serve, “Mr. Puorro added.” That begins with hiring talented professionals who know the local market because they live and work there. Their insight allows us to make decisions close to our clients and deliver the tailored service that defines Hanover. That is what it means to move Forward Together.”

The Riverhead branch represents another milestone in Hanover Bank’s long-term expansion across Suffolk County and the greater New York metropolitan area. We look forward to meeting our new neighbors, committing to the growth of the community and assisting in any way we can to help our clients achieve their financial goals.

About Hanover Community Bank and Hanover Bancorp, Inc.

Hanover Bancorp, Inc. (NASDAQ: HNVR), is a bank holding company for Hanover Community Bank, a community commercial bank focusing on highly personalized and efficient services and products responsive to client needs. Management and the Board of Directors are comprised of a select group of successful local businessmen and women who are committed to the success of the Bank by knowing and understanding the metro-New York area’s financial needs and opportunities. Backed by state-of-the-art technology, Hanover offers a full range of financial services. Hanover employs a complete suite of consumer, commercial, and municipal banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit. Hanover also offers its customers access to 24-hour ATM service with no fees attached, free checking with interest, telephone banking, advanced technologies in mobile and internet banking for our consumer and business customers, safe deposit boxes and much more. The Company’s corporate administrative office is located in Mineola, New York where it also operates a full-service branch office along with additional branch locations in the Bowery, Forest Hills, Flushing, Garden City Park, Hauppauge, Port Jefferson, Sunset Park, Rockefeller Center, New York, and Freehold, New Jersey.

Hanover Community Bank is a member of the Federal Deposit Insurance Corporation and is an Equal Housing/Equal Opportunity Lender. For further information, call (516) 548-8500 or visit the Bank’s website at www.hanoverbank.com.

Investor and Press Contact:
Lance P. Burke
Senior Executive VP – Chief Financial Officer
(516) 548-8500

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — National Healthcare Properties, Inc. (Nasdaq: NHP) (“NHP”) announced today that it will release its financial results for the quarter ended September 30, 2026 after market close on Wednesday, November 4, 2026.

NHP’s executive leadership will also host a conference call and webcast on Thursday, November 5, 2026, beginning at 10:00 a.m. ET, to review the third quarter results.

The dial in numbers for the conference call are 1-833-461-5787 (U.S. & Canada) and +1-585-542-9983 (International) and the Meeting ID is 851 315 324. Alternatively, you can pre-register for the call here. Upon pre-registering for the call, a unique dial-in code will be emailed directly to your email, avoiding any wait times on hold.

Shortly after the conclusion of the conference call, a webcast replay will be available on NHP’s investor website or by clicking here.

About National Healthcare Properties, Inc.

National Healthcare Properties, Inc. (Nasdaq: NHP) is a self-managed real estate investment trust focused on acquiring, owning and investing in a diversified portfolio of healthcare real estate, with an emphasis on providing senior housing to serve a growing elderly population in the United States. Additional information about the Company can be found on its website at nhpreit.com.

Contacts

Investors and Media:
Email: ir@nhpreit.com

SOUTH JORDAN, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2026, after the close of the stock market on Thursday, October 29, 2026. Merit plans to hold its investor conference call on the same day (Thursday, October 29, 2026) at 4:30 p.m. Eastern (3:30 p.m. Central, 2:30 p.m. Mountain, and 1:30 p.m. Pacific).

To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details.

A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at www.merit.com.

ABOUT MERIT

Founded in 1987, Merit is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling approximately 900 individuals. Merit employs approximately 7,500 people worldwide.

Contacts:
PR/Media Inquiries: Sarah Comstock Merit Medical	Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare
+1-801-432-2864	+1-443-213-0509
sarah.comstock@merit.com	mike.piccinino@icrhealthcare.com

SRX to dividend ETF holdings to shareholders 

Initial ETF to feature an actively managed digital asset hedging strategy powered by EMJX’s proprietary AI technology

NORTH PALM BEACH, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced a $1.5 million commitment to launch a new family of actively managed Exchange Traded Funds (ETFs) through its EMJX platform, marking the first step in bringing EMJX’s proprietary AI-driven investment intelligence to the broader investing public.

The ETF family will be actively managed by Eric Jackson, President, EMJX Platform and Head of Asset Management. Kupa AI, an AI fintech company co-founded by Andy Kim, will oversee the logistics of the launch.

Andy Kim is the Co-Founder of Kupa AI, which develops and operates a global suite of financial products across stocks, bonds, prediction markets, and copy trading under the Unlok brand. Prior to founding Kupa AI, Mr. Kim was Co-Founder, Chief Investment Officer, and Managing Member of Pinz Capital Management, a New York-based hedge fund focused on relative value, event-driven, special situations, and systematic market-neutral strategies across more than 40 countries. Earlier in his career, he was a hedge fund manager at leading global investment firms, including Millennium Management and Paloma Partners. Mr. Kim holds a degree in Economics and Statistics from the University of Chicago and a Master’s degree in Financial Engineering from the University of California, Berkeley.

EMJX expects its first ETF to be available to retail and institutional investors in the first quarter of 2027. The initial fund will execute a specialized hedging strategy for digital assets, powered by EMJX’s proprietary AI-driven regime model, which is designed to identify shifts in market conditions and adjust portfolio exposure across bullish, bearish, and mixed market environments.

The ETF launch represents a significant milestone in the commercialization of the EMJX platform. As previously discussed, the Company has received inbound interest from parties seeking access to the EMJX model, including ETF sponsors, digital asset treasuries, and other institutional investors. Unlike many actively managed strategies that are available only to accredited investors through private vehicles, an exchange-traded structure is expected to make EMJX’s approach accessible to any investor with a brokerage account.

“We are consistently looking for unique, technology-enabled opportunities that drive tangible value for our shareholders,” said Kent Cunningham, Chief Executive Officer of SRX Global Inc. “Bringing EMJX to market through an ETF puts our proprietary intelligence in front of a far broader universe of investors, while keeping SRX shareholders directly aligned with its success. Eric leads the investment strategy, and with Andy and the Kupa AI team overseeing launch logistics, we believe we have the right partners in place to execute. By providing the initial capital for this launch, we are backing a differentiated product built on our own technology and creating a direct link between its growth and value for our shareholders.”

In keeping with the Company’s ongoing commitment to returning value to its shareholders, SRX intends to dividend its holdings from this ETF launch directly to SRX shareholders. Additional details, including timing and record date, will be announced at a later date.

Eric Jackson, President, EMJX Platform and Head of Asset Management, added, “We are thrilled to bring this innovative family of ETFs to both retail and institutional investors. Strategies designed to actively manage digital asset volatility have largely been the domain of hedge funds and private vehicles. By leveraging EMJX’s proprietary technology, our first offering is designed to provide a disciplined hedging strategy for digital assets, addressing a critical need in today’s dynamic market. I look forward to working alongside Andy and the Kupa AI team to bring this strategy to market.”

About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “intend,” “aim,” “plan,” “may,” “could,” “target,” and similar expressions are intended to identify forward-looking statements, including statements regarding the Company’s investment strategy, capital allocation and portfolio positioning, the anticipated benefits and timing of the EMJX ETF launches, the receipt of required regulatory approvals, the performance of third parties, including Kupa AI, the form, timing, and tax treatment of any dividend of ETF holdings to shareholders, the ability to make dividend payments to shareholders, and the anticipated performance of the digital asset hedging strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks described in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy shares of any ETF. Any offering of ETF shares will be made only by means of a prospectus filed with the Securities and Exchange Commission.

Company Contact
SRX Global Inc.
Kent Cunningham, Chief Executive Officer

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
srx@kcsa.com